171 related articles for article (PubMed ID: 27881041)
1. Incidence and survival outcomes of chronic myelomonocytic leukemia in the United States.
Guru Murthy GS; Dhakal I; Mehta P
Leuk Lymphoma; 2017 Jul; 58(7):1648-1654. PubMed ID: 27881041
[TBL] [Abstract][Full Text] [Related]
2. Trends of incidence and survival of patients with chronic myelomonocytic leukemia between 1999 and 2014: A comparison between Swiss and American population-based cancer registries.
Benzarti S; Daskalakis M; Feller A; Bacher VU; Schnegg-Kaufmann A; Rüfer A; Holbro A; Schmidt A; Benz R; Solenthaler M; Stussi G; Arndt V; Bonadies N;
Cancer Epidemiol; 2019 Apr; 59():51-57. PubMed ID: 30690330
[TBL] [Abstract][Full Text] [Related]
3. Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study.
Zeidan AM; Hu X; Long JB; Wang R; Ma X; Podoltsev NA; Huntington SF; Gore SD; Davidoff AJ
Cancer; 2017 Oct; 123(19):3754-3762. PubMed ID: 28621841
[TBL] [Abstract][Full Text] [Related]
4. Blastic Transformation in Mexican Population With Chronic Myelomonocytic Leukemia.
Rivera Duarte A; Armengol Alonso A; Sandoval Cartagena E; Tuna Aguilar E
Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):532-538. PubMed ID: 28842140
[TBL] [Abstract][Full Text] [Related]
5. Incidence and survival of chronic myelomonocytic leukemia in Girona (Spain): a population-based study, 1993-2007.
Osca-Gelis G; Puig-Vives M; Saez M; Gallardo D; Solé F; Marcos-Gragera R
Leuk Res; 2012 Oct; 36(10):1262-6. PubMed ID: 22784713
[TBL] [Abstract][Full Text] [Related]
6. Patients With Therapy-Related CMML Have Shorter Median Overall Survival Than Those With De Novo CMML: Mayo Clinic Long-Term Follow-Up Experience.
Subari S; Patnaik M; Alfakara D; Gangat N; Elliott M; Hogan W; Litzow M; Al-Kali A
Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):546-9. PubMed ID: 26189785
[TBL] [Abstract][Full Text] [Related]
7. Prognostic assessment for chronic myelomonocytic leukemia in the context of the World Health Organization 2016 proposal: a multicenter study of 280 patients.
González JS; Perusini MA; Basquiera AL; Alfonso G; Fantl D; Lima WM; Nucifora E; Lazzarino C; Novoa V; de Andrade Silva MC; Larripa IB; Rocha V; Arbelbide J; Velloso EDRP; Belli CB
Ann Hematol; 2021 Jun; 100(6):1439-1449. PubMed ID: 33932168
[TBL] [Abstract][Full Text] [Related]
8. Temporal trend in survival for chronic myelomonocytic leukemia in the US: a population-based study.
Lesegretain A; Brunner A; Benzohra A; Fathi AT
Leuk Lymphoma; 2023 Dec; 64(13):2156-2164. PubMed ID: 37715313
[TBL] [Abstract][Full Text] [Related]
9. Second malignancies in survivors of chronic myelomonocytic leukemia: a U.S. population-based study.
El-Fattah MA
Leuk Lymphoma; 2017 Sep; 58(9):1-7. PubMed ID: 28092999
[No Abstract] [Full Text] [Related]
10. Cytogenetic risk stratification may predict allogeneic hematopoietic stem cell transplantation outcomes for chronic myelomonocytic leukemia.
Motohashi K; Fujisawa S; Doki N; Kobayashi T; Mori T; Usuki K; Tanaka M; Fujiwara S; Kako S; Aoyama Y; Onoda M; Yano S; Gotoh M; Kanamori H; Takahashi S; Okamoto S;
Leuk Lymphoma; 2018 Jun; 59(6):1332-1337. PubMed ID: 29032731
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire.
Park S; Labopin M; Yakoub-Agha I; Delaunay J; Dhedin N; Deconinck E; Michallet M; Robin M; De Revel T; Bernard M; Vey N; Lioure B; Lapusan S; Tabrizi R; Bourhis JH; Huynh A; Beguin Y; Socié G; Dreyfus F; Fenaux P; Mohty M
Eur J Haematol; 2013 May; 90(5):355-64. PubMed ID: 23320648
[TBL] [Abstract][Full Text] [Related]
12. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents.
Alfonso A; Montalban-Bravo G; Takahashi K; Jabbour EJ; Kadia T; Ravandi F; Cortes J; Estrov Z; Borthakur G; Pemmaraju N; Konopleva M; Bueso-Ramos C; Pierce S; Kantarjian H; Garcia-Manero G
Am J Hematol; 2017 Jul; 92(7):599-606. PubMed ID: 28370097
[TBL] [Abstract][Full Text] [Related]
13. Analyses on clinical characteristic and prognoses of 41 patients with chronic myelomonocytic leukemia in China.
Chen B; Ma Y; Xu X; Wang X; Qin W; Ji M; Lin G
Leuk Res; 2010 Apr; 34(4):458-62. PubMed ID: 19631982
[TBL] [Abstract][Full Text] [Related]
14. Blast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome.
Patnaik MM; Wassie EA; Lasho TL; Hanson CA; Ketterling R; Tefferi A
Am J Hematol; 2015 May; 90(5):411-6. PubMed ID: 25645147
[TBL] [Abstract][Full Text] [Related]
15. [Karyotypic analysis and prognosis for 41 patients with chronic myelomonocytic leukemia].
Lu Y; Yu MX; Mu QT; Wang Q; Chen ZM; Lou JY; Jin J
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Apr; 30(2):134-7. PubMed ID: 23568720
[TBL] [Abstract][Full Text] [Related]
16. Incidence and survival of therapy related myeloid neoplasm in United States.
Guru Murthy GS; Hamadani M; Dhakal B; Hari P; Atallah E
Leuk Res; 2018 Aug; 71():95-99. PubMed ID: 30048839
[TBL] [Abstract][Full Text] [Related]
17. Incidence and survival of T-cell acute lymphoblastic leukemia in the United States.
Guru Murthy GS; Pondaiah SK; Abedin S; Atallah E
Leuk Lymphoma; 2019 May; 60(5):1171-1178. PubMed ID: 30407885
[TBL] [Abstract][Full Text] [Related]
18. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant.
Ricci C; Fermo E; Corti S; Molteni M; Faricciotti A; Cortelezzi A; Lambertenghi Deliliers G; Beran M; Onida F
Clin Cancer Res; 2010 Apr; 16(8):2246-56. PubMed ID: 20371679
[TBL] [Abstract][Full Text] [Related]
19. Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution.
Tang G; Zhang L; Fu B; Hu J; Lu X; Hu S; Patel A; Goswami M; Khoury JD; Garcia-Manero G; Medeiros LJ; Wang SA
Am J Hematol; 2014 Aug; 89(8):813-8. PubMed ID: 24782398
[TBL] [Abstract][Full Text] [Related]
20. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
Harel S; Cherait A; Berthon C; Willekens C; Park S; Rigal M; Brechignac S; Thépot S; Quesnel B; Gardin C; Adès L; Fenaux P; Braun T
Leuk Res; 2015 May; 39(5):501-4. PubMed ID: 25735917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
